临床阶段眼科生物科技公司拨康视云-B(02592.HK)公布在港首次公开发售(IPO)详情，计划全球发售6,058.2万股，当中国际配售部分占90%(5,452.35万股)，香港公开发售占10%(605.85万股)，发售价为每股10.1元，预料集资近6.12亿元。每手买卖单位500股，入场费约5,100.94元。招股期由今日(24日)起至周五(27日)止，预计会于7月3日挂牌上市。联席保荐人为建银国际及华泰国际。
按发售价10.1元计，集资所得净额约5.22亿元，其中约62.4%将用于核心产品CBT-001的临床研发活动，约27.6%用于拨付持续临床研发活动及核心产品CBT-009的注册备案，约5.5%用于生产设施及商业化活动，余下4.5%为营运资金与一般企业用途。
是次招股引入2个基石投资者，包括中源协和细胞基因工程董事长龚虹嘉旗下的富策控股，以及投资机构The Reynold Lemkins Group (Asia) Limited，分别投资2,000万美元及280万美元，合共认购约1,772万股发售股份，占是次发售股份约29.25%。(gc/W)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.